Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10
L Steidler, W Hans, L Schotte, S Neirynck, F Obermeier… - Science, 2000 - science.org
L Steidler, W Hans, L Schotte, S Neirynck, F Obermeier, W Falk, W Fiers, E Remaut
Science, 2000•science.orgThe cytokine interleukin-10 (IL-10) has shown promise in clinical trials for treatment of
inflammatory bowel disease (IBD). Using two mouse models, we show that the therapeutic
dose of IL-10 can be reduced by localized delivery of a bacterium genetically engineered to
secrete the cytokine. Intragastric administration of IL-10–secreting Lactococcus lactis caused
a 50% reduction in colitis in mice treated with dextran sulfate sodium and prevented the
onset of colitis in IL-10−/− mice. This approach may lead to better methods for cost-effective …
inflammatory bowel disease (IBD). Using two mouse models, we show that the therapeutic
dose of IL-10 can be reduced by localized delivery of a bacterium genetically engineered to
secrete the cytokine. Intragastric administration of IL-10–secreting Lactococcus lactis caused
a 50% reduction in colitis in mice treated with dextran sulfate sodium and prevented the
onset of colitis in IL-10−/− mice. This approach may lead to better methods for cost-effective …
The cytokine interleukin-10 (IL-10) has shown promise in clinical trials for treatment of inflammatory bowel disease (IBD). Using two mouse models, we show that the therapeutic dose of IL-10 can be reduced by localized delivery of a bacterium genetically engineered to secrete the cytokine. Intragastric administration of IL-10–secretingLactococcus lactis caused a 50% reduction in colitis in mice treated with dextran sulfate sodium and prevented the onset of colitis in IL-10−/− mice. This approach may lead to better methods for cost-effective and long-term management of IBD in humans.
AAAS